SHENYANG, China, May 1, 2013 /PRNewswire/ -- 3SBio Inc.
(NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on
researching, developing, manufacturing and marketing
biopharmaceutical products, today announced that it has filed the
Company's Annual Report on Form 20-F for the fiscal year ended
December 31, 2012 with the U.S.
Security and Exchange Commission on April
30, 2013. The annual report on Form 20-F, which contains its
audited financial statements, can be accessed on the SEC's website
at http://www.sec.gov or on the Investor section of the Company's
website www.3sbio.com. Shareholders may also receive a hard copy of
the annual report free of charge upon request.
About 3SBio Inc.
3SBio is a leading, fully integrated, profitable biotechnology
company focused on researching, developing, manufacturing and
marketing biopharmaceutical products primarily in China. Its
focus is on addressing large markets with significant unmet medical
needs in nephrology, oncology, supportive cancer care, inflammation
and infectious diseases. With headquarters and GMP-certified
manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people.
Shares trade in the form of American Depositary Shares (ADSs) on
the NASDAQ stock market under the ticker symbol "SSRX". Please see
www.3SBio.com for more information.
Investor Contacts
Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: + 86 24 2581-1820
ir@3SBio.com
Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: + 852 8191-6991
ir@3SBio.com
SOURCE 3SBio Inc.